A novel strategy for combination chemotherapy (platinum and demethylcantharidin) via a polymer-(tandem drugs) conjugate for enhanced cancer treatment is demonstrated. Cisplatin can be released inside cell by reduction to attack DNA, while DMC will be hydrolyzed subsequently to block DNA-damage-induced defense mechanisms by serine/threonine phosphatase PP2A inhibition. Synergistic effect of the polymer-(tandem drugs) conjugate causes complete suppression of H22 liver tumor xenografts without recurrence.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: